Business
Media
Conferences
Publications
CME/CE
Resources
Subscribe

|Videos|July 22, 2022

Dr. Alam on survival differences in kidney cancer based on race and socioeconomic factors

Author(s)Urology Times staff

Ridwan Alam, MD, a urology resident at Johns Hopkins Brady Urological Institute, discusses the abstract, “Investigation of race and associated socioeconomic factors in survival outcomes for patients with renal cell carcinoma,” which he presented at the 2022 AUA Annual Meeting (abstract PD18-12).

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Related Content

Adanma Ayanambakkam, MD, discusses phase 1 data on darlifarnib plus cabozantinib in RCC

ByAdanma Ayanambakkam, MD, MS

July 28th 2026

Darlifarnib plus cabozantinib shows encouraging antitumor activity in ccRCC

ByHannah Clarke

July 27th 2026

Phase 3 trial launches of CAIX-targeted radiopharmaceutical for ccRCC

ByHannah Clarke

July 21st 2026

Casdatifan shows durable activity in metastatic clear cell renal cell carcinoma

ByHannah Clarke

July 6th 2026

Microbial dysbiosis may predict response to CBM588 in mRCC

ByRahul Winayak, MD

June 22nd 2026

Latest CME

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Jason Hafron, MD; Aaron D. Berger, MD; Arpeet Shah, MD

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Radioligand Therapy 101: The Science Behind the Strategy

Radioligand Therapy 101: The Science Behind the Strategy

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Jeremie Calais, MD, PhD; Scott T. Tagawa, MD, MS, FACP, FASCO

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Trending on Urology Times

FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC

Testosterone deficiency: FAQs from the AUA guideline

Individualizing androgen pathway therapy in mCSPC

Large registry study reports durable 10-year outcomes with focal therapy for prostate cancer

Joshua Lang, MD, MS, on integrating molecular biomarkers into clinical practice